Global life sciences company, Thermo Fisher Scientific, has announced plans to develop a facility with two new sterile filling lines in Singapore, extending its capacity for developing and manufacturing therapies and vaccines in the Asia Pacific. It will include a high-speed sterile line for live virus filling, a first of such large scale capability in Singapore, and an additional line for standard fill/finish. It will also contain cleanroom capacity, labs, warehousing, and offices.
The facility is expected to cost USD130 million and is estimated to be completed in 2022. Its manufacturing capacity will be up to 30 million sterile doses per month. It will employ over 300 people, giving it the capability to meet regional demand and respond more effectively to future health emergencies. This facility was established with the support of the Singapore Economic Development Board (EDB), highlighting the importance of government and industry collaboration in light of the Covid-19 pandemic, by ensuring the availability of critical diagnostic tests, therapies, and vaccines.
(Source: Drug Discovery and Development)
